IRVINE, Calif.--(BUSINESS WIRE)--Pharmaron, a fully integrated contract research organization (CRO) offering laboratory and manufacturing services for pharmaceutical and biotech research and development, has joined a national network of scientists on the leading edge of drug discovery and development in the fight against cancer, centered at the Frederick National Laboratory for Cancer Research.
The Frederick National Lab, sponsored by the National Cancer Institute (NCI), is managing the expansion of the Chemical Biology Consortium (CBC) to 22 sites around the country with world-class expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. Pharmaron will participate in the consortium via a research subcontract from Leidos Biomedical Research, Inc., prime contractor for the national lab.
The CBC is the discovery engine for the NCI Experimental Therapeutics (NExT) Program. The CBC is a consortium designed to facilitate the discovery and development of novel agents for the treatment of cancer by integrating chemical biology, molecular oncology research and development capabilities and resources from the government, academia and industry. Pharmaron will participate in the CBC as a Specialized Center, providing DMPK and other bio-analysis services.
As a CBC participant, Pharmaron is honored to provide R&D services to support the discovery and development of promising new molecular entities focusing on unmet medical needs in therapeutic areas not adequately addressed today.
Pharmaron’s DMPK and bioanalysis platform is a comprehensive and integrated component of the company’s drug R&D services at Pharmaron. The platform spans from discovery in vitro ADME, in vivo PK and PK/PD correlation, to regulatory compliant DMPK and bioanalysis, including metabolism studies using radioactive compounds. This platform has played a critical role in successfully advancing agents from early discovery to preclinical and clinical development phases for Pharmaron’s partners and collaborators. Pharmaron is confident that by working together closely with other members of the CBC, innovations from the CBC can be translated into novel and effective anti-cancer medicines.
Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and safety assessment to chemical & pharmaceutical development. With over 3,500 employees and operations in China, the U.S. and the UK, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, please visit www.pharmaron.com.
About the Frederick National Laboratory for Cancer Research
The Frederick National Laboratory for Cancer Research is a federal national laboratory sponsored by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). The Frederick National Lab collaborates with academic, commercial, nonprofit, and government researchers to address urgent problems in biomedical research consistent with NCI’s mission. The national lab is government-owned, contractor-operated facility with Leidos Biomedical Research Inc., as its prime contractor.